West Pharmaceutical Services (WST) Rating Increased to Buy at ValuEngine

West Pharmaceutical Services (NYSE:WST) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Separately, Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $110.50.

WST opened at $116.53 on Wednesday. The firm has a market capitalization of $9.08 billion, a P/E ratio of 42.71, a PEG ratio of 4.19 and a beta of 1.16. West Pharmaceutical Services has a 1 year low of $82.74 and a 1 year high of $125.09. The company has a quick ratio of 1.94, a current ratio of 2.67 and a debt-to-equity ratio of 0.15.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.03. The firm had revenue of $447.50 million during the quarter, compared to the consensus estimate of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. The company’s revenue was up 12.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.66 EPS. On average, research analysts expect that West Pharmaceutical Services will post 2.82 EPS for the current fiscal year.

In other news, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the completion of the sale, the senior vice president now directly owns 31,051 shares in the company, valued at approximately $3,609,057.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its holdings in shares of West Pharmaceutical Services by 13,849.8% during the 2nd quarter. Bessemer Group Inc. now owns 950,816 shares of the medical instruments supplier’s stock worth $94,407,000 after buying an additional 944,000 shares in the last quarter. Brown Advisory Inc. raised its holdings in shares of West Pharmaceutical Services by 237.8% during the 1st quarter. Brown Advisory Inc. now owns 428,433 shares of the medical instruments supplier’s stock worth $37,826,000 after buying an additional 301,604 shares in the last quarter. USS Investment Management Ltd raised its holdings in shares of West Pharmaceutical Services by 24.6% during the 2nd quarter. USS Investment Management Ltd now owns 1,087,078 shares of the medical instruments supplier’s stock worth $107,936,000 after buying an additional 214,707 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of West Pharmaceutical Services by 27.1% during the 2nd quarter. Janus Henderson Group PLC now owns 875,723 shares of the medical instruments supplier’s stock worth $86,951,000 after buying an additional 186,752 shares in the last quarter. Finally, Riverbridge Partners LLC raised its holdings in shares of West Pharmaceutical Services by 37.8% during the 3rd quarter. Riverbridge Partners LLC now owns 647,980 shares of the medical instruments supplier’s stock worth $80,006,000 after buying an additional 177,637 shares in the last quarter. Hedge funds and other institutional investors own 95.97% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Yield Curve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply